Document is current
Any future updates will be listed below
-
Authors
Yu, Xinlang
Fang, Yuan
Zhang, Jiakang
Li, Wenshan
Zhang, Yajie
Cui, Qi
Liu, Xiaoyu
Jiang, Yanjie
Liu, Qizhi
Xu, Chengcheng
Jiang, Bin https://orcid.org/0000-0002-4622-9703
Lu, Yan
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (No. 81804022)
- License Information
-
More Information
Article History
Received: 25 February 2025
Accepted: 25 August 2025
First Online: 25 September 2025
Declarations
:
: This study received approval from the Ethics Committee of Nanjing University of Chinese Medicine on December 12, 2024 (Project name: Therapeutic Effects and Mechanisms of Zhigancao Decoction Combined with Adipose-Derived Mesenchymal Stem Cells on Ameliorating MPTP-Induced Parkinson’s Disease in Mice. Ethics Approval Number: A20241201). Our study related to ADSCs was approved by the Ethics Committee of animal experiments at Nanjing Medical University on August 1, 2019 (Project name: Combined treatment with Rg1 and adipose-derived stem cells alleviates DSS-induced colitis in a mouse model. Ethics Approval Number: Ethics No.1181064). The methods were carried out in accordance with the relevant guidelines. Human abdominal or buttock adipose tissues were collected from patients receiving regenerative medicine using ADSCs at Nanjing Hospital of Chinese Medicine. Written informed consent was obtained from all study participants. The SH-SY5Y cell line was obtained from the American Type Culture Collection (CRL-2266, ATCC, ). According to ATCC, the collection of these cells was conducted in compliance with ethical standards, and informed consent was obtained from the donor.
: All authors confirm their consent for publication.
: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
